Daily Stock Analysis, AGIO, Agios Pharmaceuticals Inc, priceseries

Agios Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
54.74
Close
54.33
High
56.03
Low
53.77
Previous Close
54.85
Daily Price Gain
-0.52
YTD High
56.74
YTD High Date
Jul 2, 2020
YTD Low
27.77
YTD Low Date
Mar 18, 2020
YTD Price Change
6.81
YTD Gain
14.33%
52 Week High
56.74
52 Week High Date
Jul 2, 2020
52 Week Low
27.77
52 Week Low Date
Mar 18, 2020
52 Week Price Change
10.46
52 Week Gain
23.84%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 28. 2017
58.65
Sep 26. 2017
64.85
20 Trading Days
10.58%
Link
LONG
Jan 19. 2018
69.89
Feb 2. 2018
77.33
10 Trading Days
10.64%
Link
LONG
Apr 9. 2018
80.00
Apr 23. 2018
85.68
10 Trading Days
7.09%
Link
LONG
Oct 31. 2018
63.06
Nov 12. 2018
66.94
8 Trading Days
6.15%
Link
LONG
Feb 22. 2019
58.86
Mar 6. 2019
62.81
8 Trading Days
6.71%
Link
LONG
Nov 12. 2019
33.99
Dec 30. 2019
48.15
32 Trading Days
41.67%
Link
LONG
Apr 13. 2020
39.78
Apr 28. 2020
44.84
11 Trading Days
12.71%
Link
LONG
May 15. 2020
46.29
Jun 3. 2020
51.25
12 Trading Days
10.72%
Link
Company Information
Stock Symbol
AGIO
Exchange
NasdaqGS
Company URL
http://www.agios.com
Company Phone
617-649-8600
CEO
David Paul Schenkein
Headquarters
Massachusetts
Business Address
88 SIDNEY STREET, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001439222
About

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in applying scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism. Its products include IDH1 AND IDH2, PKR, II D-2 hydroxyglutaric aciduria, AG-221 and AG-120. The comany was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.